Hers vs Brello: Weight Loss Program Models and Pricing

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — evidence-based guidance on GLP-1 therapies, weight management, and the genetics behind every metabolic decision. Browse all Peptides & GLP-1 education.

Independent editorial review. PlexusDx has no commercial relationship with Hers or Brello, includes no affiliate links, and was not paid to publish this.

The Hers-versus-Brello question is really a household-name-versus-boutique question. One is a large consumer telehealth brand; the other a smaller compounded-GLP-1 program. This comparison, current to April 2026, focuses on how recognition, model, and commitment differ, while keeping the pharmacology in perspective.

Comparing a household name to a boutique program

Hers carries broad brand awareness and a wide catalog beyond weight care; Brello is a more focused GLP-1 offering. Name recognition can signal scale and support infrastructure, but it says little about the molecule you receive. Both routes still run through the same regulatory lanes for GLP-1 dispensing.

Inside the Hers weight model

Hers (Hims & Hers Health) operates as subscription telehealth. A provider evaluates the patient online, and eligible prescriptions are fulfilled either as branded FDA-approved GLP-1 products or as compounded semaglutide or tirzepatide via a licensed compounding pharmacy. See its official website for current program details.

Inside Brello's compounded pathway

Brello (Brello Health) runs telehealth paired with a compounding pharmacy. Its structure, medication menu, and pricing vary, so consult Brello's own site for current details at the time you read this. Functionally, the intake-review-prescribe-ship sequence mirrors what most programs in this space use.

Cost and commitment

Pricing across GLP-1 telehealth spanned roughly $200 to $700 or more per month in April 2026, covering program fees, medication, and compounded dispensing where it applies. Each brand publishes its own rates, and subscription length often changes the effective monthly figure. Rather than trust stale numbers, verify Hers and Brello at their own pricing pages before enrolling.

Same molecules, different storefronts

Whichever brand you choose, the science is identical. GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) and the dual agonist tirzepatide act on appetite and satiety the same way. The evidence — STEP (NEJM, 2021), SURMOUNT (NEJM, 2022), and SURMOUNT-OSA (NEJM, 2024) — attaches to the compound, not the marketing.

Catalog breadth beyond weight care

One practical distinction is scope. Hers sits inside a broad consumer-health catalog spanning many conditions, so weight care is one line among many, while Brello concentrates on GLP-1 therapy. Breadth can mean convenient bundling of unrelated needs; focus can mean a tighter, more specialized experience. Neither posture changes the medication you ultimately receive. If you already use a large brand for other prescriptions, consolidating may simplify billing and refills; if weight care is your sole focus, a dedicated program removes the noise around it; and it lets clinical questions get answered by a team that thinks about metabolic care all day rather than dozens of unrelated conditions.

What a genetic baseline adds

Neither storefront measures the biology it prescribes into. MC4R, central to satiety and energy balance, joins FTO, GLP1R, and TCF7L2 as pathway-level markers of your metabolic starting point. They do not predict a drug's effect; they describe the terrain. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights. PlexusDx also provides the compounds through its Weight Management Protocols — Semaglutide Injection, Semaglutide Oral, Tirzepatide Injection, and Tirzepatide Oral — and the genetic test does not predict response to any specific medication.

Independence note: PlexusDx is not affiliated with Hers or Brello; this is education, not endorsement.

More reading: GLP 1 Receptor Agonist, GLP 1 Drugs, GLP 1 Hormone, and What Is GLP 1.

Editorial disclaimer: This comparison is educational. PlexusDx has no relationship with Hers or Brello but sells semaglutide and tirzepatide through its own line, so read this as a disclosed perspective. The Precision Peptide Genetic Test maps gene-pathway influences and does not predict medication response. Speak with a qualified provider before starting any protocol.

See the alternative: explore the PlexusDx Weight Management Protocols, or begin with the Precision Peptide Genetic Test.

Frequently Asked Questions

Is a big brand like Hers safer than a smaller one like Brello?

Brand size signals scale, not medical superiority. What matters is licensed clinical oversight, a legitimate pharmacy pathway, and transparent terms — both large and boutique programs can meet those standards. Review each brand's credentialing and dispensing details on its own site before deciding.

Does Hers or Brello offer branded or compounded GLP-1?

Both can dispense branded FDA-approved products or compounded semaglutide or tirzepatide from a licensed pharmacy, depending on eligibility and availability. The specific lane affects cost and supply. Confirm which option each program is offering you at the moment you enroll.

How does PlexusDx fit alongside these brands?

PlexusDx sells semaglutide and tirzepatide through its Weight Management Protocols and pairs them with the Precision Peptide Genetic Test for upstream context in genes like MC4R. That genetic layer is the differentiator, though it never predicts response to a specific medication.

Continue learning at the PlexusDx Education Hub. Browse all Peptides & GLP-1 education.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.